Biomarker Testing Patterns and Treatment Outcomes in Patients With Advanced Non-Small Cell Lung Cancer and <i>MET</i> Exon 14 Skipping Mutations: A Descriptive Analysis From the US.

Asad Zadeh Vosta Kolaei, Fatemeh; Cai, Beilei; Kanakamedala, Hemanth; Kim, Julia; Doban, Vitalii; Zhang, Shiyu; Shi, Michael

Biomarker Testing Patterns and Treatment Outcomes in Patients With Advanced Non-Small Cell Lung Cancer and MET Exon 14 Skipping Mutations: A Descriptive Analysis From the US.

Asad Zadeh Vosta Kolaei, Fatemeh; Cai, Beilei; Kanakamedala, Hemanth; Kim, Julia; Doban, Vitalii; Zhang, Shiyu; Shi, Michael.

Afiliação

Asad Zadeh Vosta Kolaei F; Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States.
Cai B; Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States.
Kanakamedala H; Genesis Research, Hoboken, NJ, United States.
Kim J; Genesis Research, Hoboken, NJ, United States.
Doban V; Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States.
Zhang S; Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States.
Shi M; Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States.

Front Oncol ; 12: 786124, 2022.

Article em En | MEDLINE | ID: mdl-35280795